Title
Category
Credits
Event date
Cost
Venous Thromboembolism Management in Malignancy
  • Venous Thromboembolic Disease
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
Clinical staff should be knowledgeable in factors that enhance VTE risk and be able to counsel patients regarding risk factors that are modifiable. They should also understand appropriate prophylaxis regimens for high-risk patients and be educated on the signs associated with the diverse subtypes of VTE and their best courses of treatment.
Updates in Melanoma: A Focus on Neoadjuvant Approaches
  • Melanoma
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
With new regimens emerging as viable options for neoadjuvant therapy, clinicians should be aware of the changing landscape in initial cutaneous melanoma treatment options. It will be essential for the clinician to identify patients who would benefit from neoadjuvant intervention versus a more traditional surgical or systemic therapy approach.
CRS and ICANS Management in CAR T/Bispecific Antibody Therapies
  • Management of Immunotherapy-Related Toxicities
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
As these therapies continue to evolve, it is imperative that nursing policies are created/revised and shared with nursing staff to remain up to date on current clinical practice for these complications. With continued education and reinforcement of protocols, nurses can positively impact patient outcomes.
Advances in Antiemesis Management for Patients with Cancer
  • Supportive Care Topics
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
Recent clinical trials continue to enhance available data on the use of olanzapine for emesis prevention in parenteral anticancer agents with high and moderate emetogenic risk as well as for breakthrough treatment and an alternative to dexamethasone for delayed anticancer induced nausea/vomiting. Clinicians should be aware of these updates and how they apply to appropriate patients.
Updates in Metastatic Colorectal Cancer
  • Colorectal Cancer
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
As options for treatment of metastatic colorectal cancer evolve, clinicians can benefit from education about available options and criteria for selecting the appropriate option to offer their patients. An overview of these newer treatment options, and the data supporting these, should help clinicians better serve their patients with metastatic colorectal cancer.
Treatment Updates for Small Cell Lung Cancer
  • Lung Cancers
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
$0.00
After decades of no change in treatment, practice changing therapies have now been added to the NCCN Guidelines for Small Cell Lung Cancer. This activity will help clinicians keep up to date with practice-changing strategies for SCLC.
Plenary Session: Artificial Intelligence in Cancer Care: Opportunities, Challenges, and Governance
  • Best Practices
  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation
$0.00
Education in this topic is important as AI is increasingly incorporated into care settings. Practitioners may not be aware of the way AI is currently being used or of its potential future application. Additionally, healthcare professionals need to be informed of the policy environment for the safe and effective use of AI in healthcare settings.
Artificial Intelligence: Evaluation and Success Criteria for AI Tools
  • Best Practices
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
With the promise of artificial intelligence (AI) and its potential to positively impact healthcare, comes the challenge of how to assess the feasibility and value associated with implementation of AI tools.
Improving Clinical Trial Accrual: Doing More with Less
  • Best Practices
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
$0.00
Traditional recruitment to clinical trials was accomplished by outreach from the treating physician or staff associated with the clinical trial. It is important for clinicians to be aware of the logistics and the value that a clinical trial matching tool can bring to presenting a person with cancer the appropriate clinical trial.
Expanding the Reach of Clinical Trials
  • Best Practices
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
Although we have made some progress in ways of increasing clinical trial access to underserved communities, inequities persist. Education in this area is important because increasing access to clinical trials will have a positive impact on patient outcomes and help address current disparities in cancer treatment.

Pages